Evidence map›Paper›PMID 31362008›Full record

ArticleNeurotoxicology2019

Evaluation of first-line anticonvulsants to treat nerve agent-induced seizures and prevent neuropathology in adult and pediatric rats.

Liana Matson, Emily Dunn, Kari Haines, Stephanie Miller-Smith, Robyn Lee-Stubbs, Kimberly Whitten, Cherish Ardinger, Hilary McCarren, John McDonough

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotoxicology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Liana MatsonNeuroscience Branch, US Army Medical Research Institute of Chemical Defense, 8350 Ricketts Point Road, Aberdeen Proving Ground, MD, 21010, USA. Electronic address: liana.m.matson.mil@mail.mil.
Emily DunnNeuroscience Branch, US Army Medical Research Institute of Chemical Defense, 8350 Ricketts Point Road, Aberdeen Proving Ground, MD, 21010, USA.
Kari HainesNeuroscience Branch, US Army Medical Research Institute of Chemical Defense, 8350 Ricketts Point Road, Aberdeen Proving Ground, MD, 21010, USA.
Stephanie Miller-SmithNeuroscience Branch, US Army Medical Research Institute of Chemical Defense, 8350 Ricketts Point Road, Aberdeen Proving Ground, MD, 21010, USA.
Robyn Lee-StubbsOffice of the Commander, US Army Medical Research Institute of Chemical Defense, 8350 Ricketts Point Road, Aberdeen Proving Ground, MD, 21010, USA.
Kimberly WhittenComparative Pathology Department, US Army Medical Research Institute of Chemical Defense, 8350 Ricketts Point Road, Aberdeen Proving Ground, MD, 21010, USA.
Cherish ArdingerNeuroscience Branch, US Army Medical Research Institute of Chemical Defense, 8350 Ricketts Point Road, Aberdeen Proving Ground, MD, 21010, USA.
Hilary McCarrenNeuroscience Branch, US Army Medical Research Institute of Chemical Defense, 8350 Ricketts Point Road, Aberdeen Proving Ground, MD, 21010, USA.
John McDonoughNeuroscience Branch, US Army Medical Research Institute of Chemical Defense, 8350 Ricketts Point Road, Aberdeen Proving Ground, MD, 21010, USA.

Funding

Improved standard of care reactivaters and facilitative transport into the centraU01NS083448 · NINDS · U.S. ARMY MEDICAL RESEARCH INST CHEM DEF · PI MCDONOUGH, JOHN H. · 2013 to 2017
$1.6M
NINDS NIH HHS U01 NS083448
6 · The paper itself

Abstract

Risk exists for civilian exposure to nerve agents (NA), and exposure can produce prolonged seizures. Pediatric populations are at greater risk for injury or death due to the central nervous system effects of NAs. To address the need to evaluate the effectiveness of anticonvulsants, pediatric and adult animal models were established to test the effectiveness of anticonvulsant drugs for treating NA-induced seizures in pediatric populations. In this paper, median effective dose (ED50) and neuroprotective effectiveness were determined for the first-line anticonvulsant treatments diazepam and midazolam in pediatric and adult rats against sarin- and VX-induced seizures. Comparisons between treatments were made across postnatal days (PND) 21, 28, and 70 in rats of both sexes. We observed high efficacy and potency of midazolam and diazepam, with low variation in doses across the ages or sexes. These data are important for informing adult and pediatric dosing recommendations for NA-induced seizures.

Indexed as

AgingAnimalsAnimals, NewbornAnticonvulsantsDiazepamDose-Response Relationship, DrugElectrocorticographyFemaleMaleMidazolamNerve AgentsNervous System DiseasesNeuroprotective AgentsOrganothiophosphorus CompoundsPregnancyRatsAnticonvulsantsDiazepamMidazolamNerve AgentsNeuroprotective AgentsOrganothiophosphorus CompoundsSarinVX-agentDiazepamMidazolamSarinSex differencesStatus epilepticusVX

Identifiers

PMID31362008
PMCPMC6871769

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.